Cargando…

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

BACKGROUND AND AIM: Many studies indicated that eltrombopag and romiplostim could improve hematopoietic function in patients with myelodysplastic syndromes (MDS), but their toxicity and efficacy were not known. This meta-analysis aimed to investigate the safety and efficacy of eltrombopag and romipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Fanqiao, Chen, Xiuqiong, Yu, Shunjie, Ren, Xiaotong, Liu, Zhaoyun, Fu, Rong, Li, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727449/ https://www.ncbi.nlm.nih.gov/pubmed/33324559 http://dx.doi.org/10.3389/fonc.2020.582686

Ejemplares similares

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
por: Meng, Fanqiao, et al.
Publicado: (2020)

Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance
por: Li, Lijuan, et al.
Publicado: (2022)

The expression and clinical significance of CD59 and FLAER in Chinese adult AML patients
por: Li, Lijuan, et al.
Publicado: (2021)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
por: Schmitt, Nanni, et al.
Publicado: (2021)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
por: Platzbecker, U, et al.
Publicado: (2014)

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
por: Mittelman, Moshe, et al.
Publicado: (2023)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
por: Wilkins, Cy R., et al.
Publicado: (2022)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
por: Vicente, Alana, et al.
Publicado: (2020)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes
por: Chen, Qiuni, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
por: Wang, Eunice S, et al.
Publicado: (2012)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

Abnormal Ferroptosis in Myelodysplastic Syndrome
por: Lv, Qi, et al.
Publicado: (2020)

Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes
por: Xiao, Xia, et al.
Publicado: (2020)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
por: de Oliveira, Fernanda Lubiana, et al.
Publicado: (2023)

Eltrombopag in Good's Syndrome
por: Kristiansen, Håvard Anton, et al.
Publicado: (2014)

Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients
por: Hamed, Eman Mostafa, et al.
Publicado: (2023)

Editorial: Risk-stratification in myelodysplastic syndromes
por: Breccia, Massimo, et al.
Publicado: (2022)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Pericole, Fernando Vieira, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tkscc02m7p4n2dcmjvph0m98l1